- InterView
- "Recruiting a company to co-develop pitavastatin+ezetimibe"
- by Kim, Jin-Gu Oct 30, 2024 05:54am
- Shinil Pharmaceutical will collaborate with other biopharmaceutical company to co-develop a generic 'pitavastatin+ezetimibe' combination drug for treating hyperlipidemia. Through joint-collaboration, Shinil Pharmaceutical plans to improve not only the contract manufacturing of medicines but also cost savings and productivity. In the mean
- Company
- Difficulty expanding indications for antibody-drug conjugate
- by Moon, sung-ho Oct 30, 2024 05:54am
- Drug candidates that received much expectation as next-generation antibody-drug conjugates (ADCs) based on the success of Enhertu are on a struggling path to reimbursement in Korea. &160; Although the companies aimed to expand the scope of coverage of their drugs based on their effectiveness in specific cancer types, the expectations damped
- Policy
- Gvnt agrees on the need for dispensing substitute drugs
- by Lee, Jeong-Hwan Oct 30, 2024 05:54am
- In this year's NA Audit, the Minister of Health and Welfare Kyoo-Hong Cho said that he would prioritize the ‘dispensing of substitute drugs’ as a solution to the problem of unstable supply of medicines such as cold medicines that are often out of stock. Two bills related to alternative dispensing were submitted to the National Assembly
- Company
- Dupixent sales skyrocket with 'expanded indications'
- by Son, Hyung Min Oct 30, 2024 05:54am
- Sales for 'Dupixent,' a biological agent developed by Sanofi, continue to skyrocket. Net sales for Dupixent from Q1 to Q3 of 2024 reached 10 billion euros. The analysis suggests that Dupixent's added indications to treat various immune diseases, including atopic dermatitis, asthma, esophagitis, and chronic obstructive pulmonary disease (COPD), h
- Product
- KMA ‘non-face-to-face Wegovy prescriptions cause harm'
- by Kang, Shin-Kook Oct 30, 2024 05:53am
- A Korean doctor's association has called for an immediate halt to the government's plan to allow non-face-to-face medical treatment. The Korean Medical Association (Chairman Hyun-Taek Lim) issued a statement on the 28th claiming, “The government should immediately stop allowing all non-face-to-face medical treatment as its pilot project
- Opinion
- [Reporter's View] Super precision medicine
- by Eo, Yun-Ho Oct 30, 2024 05:53am
- Super Precision medicine. New drugs have been developed to selectively target with more significant efficacy than before. Lately, news articles related to anticancer agents have frequently covered keywords related to genetic mutations, including MET, RET, ALK, EGFR, and ROS1. Customized treatments are becoming available, where effective t
- Company
- "Early intervention" needed for treating multiple myeloma
- by Whang, byung-woo Oct 29, 2024 05:49am
- The survival rate of patients with multiple myeloma increased following new drug development. However, concerns have been raised that South Korea's survival rate is still far from that of advanced countries. Expert opinions indicate that the Korean medical treatment field changes with new drug approvals and reimbursement listings, yet patien
- Company
- Will the third time be the charm for Mylotarg?
- by Eo, Yun-Ho Oct 29, 2024 05:49am
- The industry’s attention is focused on whether the insurance reimbursement discussions for the acute myeloid leukemia drug ‘Mylotarg’ will make progress this time. According to the industry sources, Pfizer Korea’s acute myeloid leukemia (AML) drug ‘Mylotarg (gemtuzumab ozogamicin)’ is set to be submitted to the Health Insurance Revi
- Company
- ABL Bio receives ₩7B as milestone payment from Sanofi
- by Kim, Jin-Gu Oct 29, 2024 05:49am
- ABL Bio has received additional milestone payments from Sanofi for its degenerative brain disease treatment candidate ‘ABL301’. Including the upfront payment., ABL Bio will receive a total of KRW 170 billion, which includes the upfront payment. On 28 February, ABL Bio announced the completion of the manufacturing technology transfer o
- Policy
- Low reimb approval rate hinders Soliris’s use for aHUS
- by Lee, Tak-Sun Oct 29, 2024 05:49am
- The industry’s eyes are on whether the preliminary reimbursement review process for Soliris, a treatment for the rare disease aHUS (atypical hemolytic uremic syndrome), will be eased in Korea. Until now, patients wishing to use Soliris for aHUS with reimbursement had to pass a preliminary review process. However, the problem is its low
